Analysts Set GSK plc (LON:GSK) Target Price at GBX 1,805.83

Shares of GSK plc (LON:GSK) have been given an average rating of “Moderate Buy” by the seven research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is GBX 1,805.83 ($22.32).

GSK has been the topic of several recent analyst reports. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Tuesday, January 7th. Berenberg Bank lowered their target price on shares of GSK from GBX 1,820 ($22.49) to GBX 1,600 ($19.77) and set a “buy” rating on the stock in a research note on Friday, November 29th.

Insider Buying and Selling

In related news, insider Jonathan Symonds acquired 1,500 shares of GSK stock in a transaction dated Friday, December 20th. The shares were purchased at an average cost of GBX 1,315 ($16.25) per share, with a total value of £19,725 ($24,375.93). 1.61% of the stock is currently owned by corporate insiders.

GSK Trading Up 1.6 %

LON:GSK opened at GBX 1,465.50 ($18.11) on Friday. The business has a 50 day moving average of GBX 1,358.76. GSK has a 12 month low of GBX 1,282.50 ($15.85) and a 12 month high of GBX 1,823.50 ($22.53). The company has a market cap of £59.79 billion, a PE ratio of 1,296.90, a PEG ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73.

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) earnings per share (EPS) for the quarter. GSK had a return on equity of 33.30% and a net margin of 12.83%. Research analysts predict that GSK will post 175.980975 earnings per share for the current year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.